G6PD, CPTAC-204 - CPTAC Assay Portal (original) (raw)

Please include the following statement when referencing the CPTAC Assay Portal

We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Protein Sequence hover to view complete sequence

CPTAC-205: View additional GGYFDEFGIIR data
CPTAC-2734: View additional GGYFDEFGIIR data
CPTAC-2734: View additional GGYFDEFGIIR data

10 20 30 40 50
MAEQVALSRT QVCGILREEL FQGDAFHQSD THIFIIMGAS GDLAKKKIYP
60 70 80 90 100
TIWWLFRDGL LPENTFIVGY ARSRLTVADI RKQSEPFFKA TPEEKLKLED
110 120 130 140 150
FFARNSYVAG QYDDAASYQR LNSHMNALHL GSQANRLFYL ALPPTVYEAV
160 170 180 190 200
TKNIHESCMS QIGWNRIIVE KPFGRDLQSS DRLSNHISSL FREDQIYRID
210 220 230 240 250
HYLGKEMVQN LMVLRFANRI FGPIWNRDNI ACVILTFKEP FGTEGRGGYF
260 270 280 290 300
DEFGIIRDVM QNHLLQMLCL VAMEKPASTN SDDVRDEKVK VLKCISEVQA
310 320 330 340 350
NNVVLGQYVG NPDGEGEATK GYLDDPTVPR GSTTATFAAV VLYVENERWD
360 370 380 390 400
GVPFILRCGK ALNERKAEVR LQFHDVAGDI FHQQCKRNEL VIRVQPNEAV
410 420 430 440 450
YTKMMTKKPG MFFNPEESEL DLTYGNRYKN VKLPDAYERL ILDVFCGSQM
460 470 480 490 500
HFVRSDELRE AWRIFTPLLH QIELEKPKPI PYIYGSRGPT EADELMKRVG
510 515
FQYEGTYKWV NPHKL

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node

to view detailed assay information below

All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader


Assay Details for CPTAC-205 Collapse assay details

Data source: Panorama

Official Gene Symbol

G6PD

Peptide Sequence

GGYFDEFGIIR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

247

Peptide End

257

CPTAC ID

CPTAC-205

Peptide Molecular Mass

1,272.6139

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Fred Hutchinson Cancer Research Center

Submitting Lab PI

Amanda Paulovich


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C and 15N at C-terminus R

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y8 (1+) | 9.6 | 8.8 | 6.7 | 18.4 | 12.9 | 15.6 | 20.8 | 15.6 | 17 | 15 | 25 | 15 | | y7 (1+) | 9.3 | 6.3 | 6.2 | 17 | 10.4 | 14.5 | 19.4 | 12.2 | 15.8 | 15 | 25 | 15 | | y6 (1+) | 13.5 | 6.5 | 5.6 | 18.8 | 9.5 | 12.6 | 23.1 | 11.5 | 13.8 | 15 | 25 | 15 | | sum | 7.3 | 6.3 | 5.9 | 16.1 | 10.6 | 14.3 | 17.7 | 12.3 | 15.5 | 15 | 25 | 15 |



Additional Resources and Comments


Assay Details for CPTAC-204 Collapse assay details

Data source: Panorama

Official Gene Symbol

G6PD

Peptide Sequence

NSYVAGQYDDAASYQR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

105

Peptide End

120

CPTAC ID

CPTAC-204

Peptide Molecular Mass

1,806.7809

Species

Homo sapiens (Human)

Assay Type

Direct MRM

Matrix

cell line lysate pool

Submitting Laboratory

Fred Hutchinson Cancer Research Center

Submitting Lab PI

Amanda Paulovich


Publication

View Details (opens in a new window)

Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. Kennedy JJ, Abbatiello SE, Kim K, Yan P, Whiteaker JR, Lin C, Kim JS, Zhang Y, Wang X, Ivey RG, Zhao L, Min H, Lee Y, Yu MH, Yang EG, Lee C, Wang P, Rodriguez H, Kim Y, Carr SA, Paulovich AG. Nat Methods. 2014 Feb;11(2):149-55. doi: 10.1038/nmeth.2763. Epub 2013 Dec 8. PMID: 24317253


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

5500 QTRAP (ABSCIEX)

Internal Standard

peptide

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C,15N

LC

nanoLC-Ultra 2D, cHiPLC-nanoflex (Eksigent)

Column Packing

ChromXP C18-CL, 3 um, 120A

Column Dimensions

150 x 0.075 mm

Flow Rate

500 nL / min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y10 (1+) | 9.8 | 9.3 | 4.6 | 13.2 | 9.6 | 5.1 | 16.4 | 13.4 | 6.9 | 15 | 25 | 15 | | y9 (1+) | 7.7 | 6.7 | 4.6 | 11 | 8.1 | 4.5 | 13.4 | 10.5 | 6.4 | 15 | 25 | 15 | | y8 (1+) | 9.1 | 7.3 | 3.8 | 9.1 | 7 | 6.3 | 12.9 | 10.1 | 7.4 | 15 | 25 | 15 | | sum | 6.5 | 6.4 | 4.1 | 8.3 | 6.8 | 4.6 | 10.5 | 9.3 | 6.2 | 15 | 25 | 15 |



Additional Resources and Comments


Assay Details for CPTAC-2734 Collapse assay details

Data source: Panorama

Official Gene Symbol

G6PD

Peptide Sequence

GGYFDEFGIIR

Modification Type

unmodified

Protein - Site of Modification

N/A

Peptide - Site of Modification

N/A

Peptide Start

247

Peptide End

257

CPTAC ID

CPTAC-2734

Peptide Molecular Mass

1,272.6139

Species

Homo Sapiens

Assay Type

Direct MRM

Matrix

Tumor Digest

Submitting Laboratory

Washington University in St. Louis

Submitting Lab PI

Reid Townsend


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument

ThermoFisher Q-Exactive

Internal Standard

13 fmol on column

Peptide Standard Purity

>95%

Peptide Standard Label Type

13C and 15N at C-terminus R

LC

Easy-nLC 1000 Thermo Scientific

Column Packing

C18

Column Dimensions

75 um x 50 cm

Flow Rate

300 nL/min


Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader


Repeatability

Data source: Panorama

| | Average intra-assay CV(within day CV) | Average inter-assay CV(between day CV) | Total CVequation | n= | | | | | | | | | | | ---------------------------------------- | -------------------------------------- | --------------------------------------------------------------------------------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | ------- | ------- | -------- | | Fragment ion / Transition | Low | Med | High | Low | Med | High | Low | Med | High | Low | Med | High | | y5 (1+) | 9.7 | 4.6 | 3 | 10.6 | 3.9 | 3.2 | 14.4 | 6 | 4.4 | 15 | 15 | 15 | | y6 (1+) | 5.6 | 1.5 | 2.1 | 9.1 | 1.9 | 3.3 | 10.7 | 2.4 | 3.9 | 15 | 15 | 15 | | y8 (1+) | 6.1 | 4.2 | 3.5 | 9 | 4.7 | 3.9 | 10.9 | 6.3 | 5.2 | 15 | 15 | 15 | | sum | 6 | 2.7 | 2.7 | 8.6 | 2.7 | 3.2 | 10.5 | 3.8 | 4.2 | 15 | 15 | 15 |



Additional Resources and Comments